Candidemia: Species involved, virulence factors and antimycotic susceptibility

New Microbiologica

Volumn 35, Issue 4, 2012, Pages 459-468

  De Luca, Concetta ^a   Guglielminetti, Maria ^b   Ferrario, Antonella ^a   Calabrò, Maria ^a   Casari, Erminia ^a  

^a HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^b UNIVERSITY OF PAVIA   (Italy)

Author keywords

Antimycotic susceptibility; Candidemia; Phospholipase; Protease; Virulence factors

Indexed keywords

AMPHOTERICIN B; ANTIFUNGAL AGENT; VIRULENCE FACTOR;

ADULT; AGED; ARTICLE; CANDIDA; CANDIDEMIA; DRUG EFFECT; FEMALE; GENE EXPRESSION REGULATION; GENETICS; HUMAN; ISOLATION AND PURIFICATION; MALE; METABOLISM; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MIDDLE AGED;

ADULT; AGED; AGED, 80 AND OVER; AMPHOTERICIN B; ANTIFUNGAL AGENTS; CANDIDA; CANDIDEMIA; FEMALE; GENE EXPRESSION REGULATION, FUNGAL; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; VIRULENCE FACTORS; YOUNG ADULT;

CANDIDA; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA PARAPSILOSIS;

EID: 84869180184     PISSN: 11217138     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. BASSETTI M., ANSALDI F., NICOLINI L., MALFATTO E., MOLINARI M.P., MUSSAP M., RABESCO B., BOBBIO PALLAVICINI F., ICARDI G., VISCOLI C. (2009). Incidence of candidaemia and relationship with fluconazole use in an intensive care unit. J. Antimicrob. Chemother. 64, 625-629.
2. BASSETTI M., TAMASSO L., NICCO E., MOLINARI M.P., MUSSAP M., VISCOLI C. (2011). Epidemiology, species distribution, antifungal sisceptibility and outcome of nosocomial candidemia in a tertiary care hospital in Italy. PLoS ONE. 6 (9), 1-6.
3. BEN-AMI R., WEINBERGER M., ORNI-WASSERLAUF R., SCHARTZ D., ITZHAKI A., LAZAROVITCH T., BASH E., AHARONI Y., MOROZ I., GILADI M. (2008). Time to blood culture positivity as a marker for catheter-related candidemia. J. Clin. Microbiol. 46, 2222-2226.
4. BLUMBERG H.M., JARVIS W.R., SOUCIE J.M., EDWARDS J.E., PATTERSON J.E., PFALLER M.A., RANGEL-FRAUSTO M.S., RINALDI M.G., SAIMAN L., WIBLIN R.T., WENZEL R.P. NATIONAL EPIDEMIOLOGY OF MYCOSES SURVEY (NEMIS) STUDY GROUP. (2001). Risk factors for can-didal bloodstream infections in surgical intensive care unit patients: the NEMIS prospective multicenter study. The National Epidemiology of Mycosis Survey. Clin. Infect. Dis. 33 (2), 177-186. (Pubitemid 32643332)
5. COSTA C.R., PASSOS X.S., HASIMOTO L.K., LUCENA P., FERNANDES O., SILVA M. (2010). Differences in ex-oenzyme production and adherence ability of Candida spp. isolates from catheter, blood and oral cavity. Rev. Inst. Med. Trop. Sao Paulo. 52 (3), 139-143.
6. CISTERNA R., EZPLETA G., TELLERIA O., GUINEA J., REGUERIO B., GARCIA-RODRIGUEZ J., ESPERALBA J., THE SPANISH CANDIDEMIA SURVEILLANCE GROUP. (2010). Nationwide sentinel surveillance of bloodstream Candida infections in 40 tertiary care hospital in spain. J. Clin. Microbiol. 48 (11), 4200-4206.
7. DAGDEVIREN M., CERIKCIOGLU N., KARAVUS M. (2005). Acid proteinase, phospholipase and adherence properties of Candida parapsilosis strains isolated from clinical specimens of hospitalised patients. Mycosis. 48, 321-326. (Pubitemid 41656978)
8. DAS I., JUMAA P., NIGHTINGALE P., PATEL M. (2008). The pattern of candidaemia in a tertiary referral hospital in the United Kingdom. Abstract P1962 ECMIDD.
9. DIEKEMA D.J., MESSER S.A., BOYKEN L.B., HOLLIS R.J., KROEGER J., TENDOLKAR S., PFALLER M.A. (2009). In vitro activity of seven systemically active antifungal agents against a large global collection of rare Candida species as determined by CLSI broth microdilution methods. J. Clin. Microbiol. 47, 3170-3177.
10. FRASER V.J., JONES M., DUNKEL J., STORFER S., MEDOFF G., DUNAGAN W.C. (1992). Candidemia in a tertiary care hospital: epidemiology, risk factors, and predictors of mortality. Clin. Infect. Dis. 15 (3), 414-421.
11. FRIDKIN S.K. (2005). The changing face of fungal infections in health care settings. Clin. Infect. Dis. 41(10), 1455-1460. (Pubitemid 41579989)
12. GAREY K.W., REGE M., PAI M.P., MINGO D.E., SUDA K.J., TURPIN R.S., BEARDEN D.T. (2006). Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi-institutional study. Clin. Infect. Dis. 43 (1), 25-31. (Pubitemid 43939072)
13. GUDLAUGSSON O., GILLESPIE S., LEE K., VANDE BERGE J., HU J., MESSER S., HERWALDT L., PFALLER M., DIEKEMA D. (2003). Attributable mortality of noso-comial candidemia, revisited. Clin. Infect. Dis. 37 (9), 1172-1177. (Pubitemid 37372504)
14. GULTEKIN B., EYGOR M., TIRYAKI Y., KIRDAR S., AYDIN N. (2001). Investigation of antifungal susceptibilities and some virulence factors of Candida strains isolated from blood cultures and genotyping by RAPD-PCR. Mikrobiyol Bul. 45 (2), 306-317.
15. HAJJEH R.A., SOFAIR A.N., HARRISON L.H., LYON G.M., ARTHINGTON-SKAGGS B.A., MIRZA S.A., PHELAN M., MORGAN J., LEE-YANG W., CIBLAK M.A., BENJAMIN L.E., SANZA L.T., HUIE S., YEO S.F., BRANDT M.E., WARNOCK D.W. (2004). Incidence of bloodstream infections due to Candida species and in vitro susceptibilities of isolates collected from 1998 to 2000 in a population-based active surveillance program. J. Clin. Microbiol. 42 (4), 1519-1527. (Pubitemid 38500790)
16. HARBARTH S., FERRIERE K., HUGONNET S., RICOU B., SUTER P., PITTET D. (2002). Epidemiology and prognostic determinants of bloodstream infections in surgical intensive care. Arch. Surg. 137 (12), 1353-1359. (Pubitemid 35429592)
17. IBRAHIM E.H., SHERMAN G., WARD S., FRASER V.J., KOLLEF M.H. (2000). The influence of inadequate antimicrobial treatment of bloodstream infections on patient outcomes in the ICU setting. Chest. 118 (1), 146-155. (Pubitemid 30485502)
18. ISHIKAWA T., TAKATA T., AKAMATSU S, HATAKENAKA K., MATSUMOTO S., MAKI K., IKEDA F., TAMAI R., TAMURA K. (2010). Analysis of Candida glabrata strains with reduced sensitivity to Micafungin in vitro isolated from a patient with persistent candidemia. Jpn. J. Infect. Dis. 63, 332-337.
19. LABELLE A.J., MICEK S.T., ROUBINIAN N., KOLLEF M.H. (2008). Treatment-related risk factors for hospital mortality in Candida bloodstream infections. Crit. Care Med. 36 (11), 2967-2972.
20. MARR K.A. (2004). Invasive Candida infections: the changing epidemiology. Oncology (Williston Park) (Suppl. 13), 9-14.
21. MIKULSKA M., BASSETTI M., RATTO S., VISCOLI C. (2001). Invasive Candidiasis in non-hematological patients. Mediterr. J. Hematol. Infect. Dis. 3 (1), e2011007.
22. MOCHON A.B., YE J., KAYALA M.A., WINGARD J.R., CLANCY C.J., NGUYEN M.H., FELGNER P., BALDI P., LIU H. (2010). Serological profiling of Candida albicans protein microarray reveals permanent host-pathogen interplay and stage-specific responses during Candidemia. PLoS Pathog. 6 (3), e1000827.
23. MOHAN DAS V., BALLAI M. (2008). Proteinase and phos-pholipase activity as virulence factors in Candida species from blood. Rev. Iberoam. Micol. 25 (4), 208-210.
24. MORACE G., BORGHI E. (2010). Fungal infections in ICU patients: epidemiology and the role of diagnostics. Minerva Anestesiol. 76, 950-956.
25. MORRELL M., FRASER V.J., KOLLEF M.H. (2005). Delayng the empiric treatment of Candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality. Antimicrob. Agents Chemother. 49, 3640-3645. (Pubitemid 41233011)
26. NOLLA-SALAS J., SITGES-SERRA A., LEON-GIL C., MARTINEZ-GONZALEZ J., LEON-REGIDOR M.A., IBANEZEZ-LUCIA P., TORRES-RODRIGUEZ J.M. (1997). Candidemia in non-neutropenic critically ill patients: analysis of prognostic factors and assessment of systemic antifun-gal therapy. Study Group of Fungal Infection in the ICU. Intensive Care Med. 23 (1), 23-30. (Pubitemid 27067892)
27. NUCCI M., MARR K.A. (2005). Emerging fungal diseases. Clin. Infect. Dis. 41 (4), 521-526. (Pubitemid 41099648)
28. OSTROSKY-ZEICHNER L., REX J.H., PAPPAS P.G., HAMILL R.J., LARSEN R.A., HOROWITZ H.W., POWDERLY W.G., HYSLOP N., KAUFFMAN C.A., CLEARY J., MANGINO E., LEE J. (2003). Antifungal susceptibility survey of 2,000 bloodstream Candida isolates in the United States. Antimicrob. Agents Chemother. 47, 3149-3154. (Pubitemid 37229571)
29. OXMAN D.A., CHOW J.K., FRENDL G., HADLEY S., HERSHKOVITZ S., IRELAND P., MCDERMOTT L.A., TSAI K., MARTY F.M., KONTOYANNIS D.P., GOLAN Y. (2010). Candidaemia associated with decreased in vitro fluconazole susceptibility: is Candida speciation predictive of the susceptibility pattern? J. Antimicrob. Chemother. 65, 1460-1465.
30. PAPPAS P.G., REX J.H., LEE J., HAMILL R.J., LARSEN R.A., POWDERLY W., KAUFFMAN C.A., HYSLOP N., MANGINO J.E., CHAPMAN S., HOROWITZ H.W., EDWARDS J.E., DISMUKES W.E.; NIAID MYCOSES STUDY GROUP. (2003). A prospective observational study of can-didemia: epidemiology, therapy, and influences on mortality in hospitalized adult and pediatric patients. Clin. Infect. Dis. 37 (5), 634-643. (Pubitemid 37100802)
31. PAPPAS P.G., REX J.H., SOBEL J.D., FILLER S.G., DISMUKES W.E., WALSH T.J., EDWARDS J.E.; INFECTIOUS DISEASES SOCIETY OF AMERICA. (2004). Guidelines for treatment of candidiasis. Clin. Infect. Dis. 38 (2), 161-189. (Pubitemid 38113025)
32. PEREIRA G.H., MULLER P.R., SZESZS M.W., LEVIN A.S., MELHEM M.S. (2010). Five-year evaluation of bloodstream yeast infections in a tertiary hospital: the predominance of non-C. albicans Candida species. Med. Mycol. 48 (6), 839-842.
33. SENEVIRTATNE C.J., WONG S.S.W., YUEN K.Y., MUERMAN J.H., PARNANEN P., VAARA M., SAMARANAYAKE L.P. (2011). Antifungal susceptibility and virulence attributes of bloodstream isolates of Candida from Hong Kong and Finland. Mycopathologia. DOI 10.1007/s11046-011-944-4.
34. STYLIANAKIS A., PAPAIOANNOU V., TSIPLAKOU S., PAPANIKOLAOU P., TSOPELAS K., PANAGOPOULOU A., KARRA C., KOUTSOUKOU A. (2010). Antifungal susceptibility patterns of Candida isolates originated from invasive candidiasis. CMI. 16 (2), S221.
35. TORTORANO A.M., KIBBLER C., PEMAN J., BERNHARDT H., KLINGSPOR I., GRILLOT R. (2006). Candidaemia in Europe: epidemiology and resistance. Int. J. Antimicrob. Agents. 27, 359-3566.
36. TRICK W.E., FRIDKIN S.K., EDWARDS J.R., HAJJEH R.A., GAYNES R.P., NATIONAL NOSOCOMIAL INFECTIONS SURVEILLANCE SYSTEM HOSPITALS. (2002). Secular trend of hospital-acquired candidemia among intensive care unit patients in the United States during 1989-1999. Clin. Infect. Dis. 35 (5), 627-630.
37. TSANG C.S.P., CHU F.C.S., LEUNG W.K., JIN L.J., SAMARANAYAKE L.P., SIU S.C. (2007). Phospholipase, proteinase and haemolytic activies of Candida al-bicans isolated from oral cavities of patients with type 2 diabetes mellitus. J. Med. Microbiol. 56, 1393-1398. (Pubitemid 350105610)
38. TUMBARELLO M., POSTERARO B., TRECARICHI E.M., FIORI B., ROSSI M., PORTA R., DE GAETANO DONATI K., LA SORDA M., SPANU T., FADDA G., CAUDA R., SANGUINETTI M. (2007). Biofilm production by Candida species and inadequate antifungal therapy as predictors of mortality for patients with candidemia. J. Clin. Microbiol. 45 (6), 1843-1850. (Pubitemid 46933916)
39. UPPULURI P., CHATURVEDI A.K., SRINIVASAN A., BANERJEE M., RAMASUBRAMANIAM A.K., KÖHLER J.R., KADOSH D., LOPEZ-RIBOT J.L. (2010). Dispersion a san important step in the Candida albicans biofilm developmental cycle. PLoS Pathog. 6 (3): e1000828.
40. VISCOLI C, GIRMENIA C, MARINUS L, COLLETTE L, MARTINO P, VANDERCAM B, DOYEN C, LEBEAU B, SPENCE D, KREMERY V, DE PAUW B, MEUNIER F, THE INVASIVE FUNGAL INFECTION GROUP OF THE EORTC. (1998). Candidemia in cancer patients: a prospective, multicenter surveillance study by the Invasive Fungal Infection Group (IFIG) of the European Organization for Research and Treatment of Cancer (EORTC). Clin. Infect. Dis. 28, 1071-1079.
41. ZAOUTIS T.E., ARGON J., CHU J., BERLIN J.A., WALSH T.J., FEUDTNER C. (2005). The epidemiology and attributable outcomes of candidemia in adults and children hospitalized in the United States: a propensity analysis. Clin. Infect. Dis. 41 (9), 1232-1239. (Pubitemid 41532664)